FDA approves another SGLT2 inhibitor for adults with CKD

Empagliflozin (Jardiance) is now indicated to reduce the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression. Approval was based on the phase 3 EMPA-KIDNEY trial, in which empagliflozin reduced the risk of kidney disease progression or CV death by 28% compared with placebo. The drug was also associated with a significant reduction in new or recurrent hospitalization compared with placebo.